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The cxposurc of mouse peritoneal macrophages tocholesterol linoleatc-containing artificial ipoproteins can lead to inwacellular ceroid accumu- 
lation. This can be used as a model to study the role ofoxidation in macrophage uptake oflipoprotcins containing unstttnmtcd fatty acids,considcrd 
by many as a primary event in atherosclerotic plaque formation. Our studies how that ascorbic acid can both inhibil and promow the formation 
ofceroid in such a model system. The transition metal copper (Cu(l1)) further elevales ceroid accumulation and EDTA, a metal chelator. inhibits 
it. When trace levels of transition metals arc p~,esent, low concentrations of ascorbic acid can clcvatc ceroid formation. This pro- and antioxidant 
characteristic of ascorbic acid was confirmed by moniloring the generation of oxidants by various concentrations of ascorbic acid, assessed by 
benzoic acid hydroxylation or the fragmentation of BSA. WC discuss these observations in the context of an appnrcnl increase in ascorbic acid 
oxidation and elevated severity of atherosclerosis in diabetes mcllitus. 
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1. INTRODUCTION 
Complications of’ diabetes mellitus may be, in part, 
due to an increase in oxidative stress [121. An enhanced 
level of oxidative stress in an organism may result from 
an increase in free radical production, a reduction in 
antioxidant defences, or both. Indeed, antioxidant de- 
fences eem to be compromised in diabetes [3-51 and an 
increase in plasma markers of lipid peroxidation occurs 
in diabetic microangiopathy [6]. 
protein to glucose [l 11. This was discussed in the context 
of alterations in protein fluorescence known to occur in 
vivo [I 11. However, the possible contribution of AA 
oxidation to oxidative stress in diabetes must also he 
considered, especially in the light of the likely role of 
oxidative stress in the life-threatening complication of 
atherosclerosis. The severity of atherosclerosis ele- 
vated in diabetes and accounts for over 50% of deaths 
t141. 
Among the antioxidants preventing free radical-in- 
duced oxidation of lipids is ascorbic acid (AA), a watcr- 
soluble antioxidant [7] which may be able to recycle 
vitamin E [S], a major lipid-associated antioxidant. In 
diabetes there appears to be an alteration in AA metab- 
olism, characterised by decreased levels of plasma AA 
and increased levels of the oxidation product, dehy- 
droascorbic acid [9]. AA supplementation has therefore 
been proposed as a therapeutic approach to oxidative 
stress in diabetes. 
However, AA can oxidisc in the presence of transition 
metals such as iron and copper, generating free radicals 
and protein-reactive aldehydes [ 10,l I]. The handling of 
transition metals appears to be altered in diabetes 
[12,13]. The possibility that protein-reactive aldehydes, 
produced during transition metal-catalysed AA oxida- 
tion, contribute to diabetic complications has been 
raised [l 11. AA can induce changes in protein structure 
and fluorescence similar to those caused by exposure of 
Evidence in favour of oxidative stress as a contribu- 
tory factor to atherosclerosis has become extensive 
[ 15,161. In atherosclerotic lesions, the lipid-laden foam 
cells have been identified as macrophages [17,18]. The 
main source of lipid is thought to be LDL, probably 
oxidatively modified LDL, which has been detected in 
human lesions using monoclonal antibodies [19]. Oxi- 
dised LDL is avidly taken up by macrophages and re- 
sults in the appearance within macrophages of ceroid 
pigment, an autofluorescent polymer of oxidised lipid 
and protein, probably at least partly composed of oxi- 
dised LDL [20-231. The cause of oxidation of LDL 
during atherogenesis uncertain. One possible factor 
is the availability of transition metals as catalysts for 
such oxidative reactions [24]. 
Corrqm~dcmce addrm: J.V. Hunt, Department of Pathology, Tennis 
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We have used a model system to study ceroid accu- 
mulation in mouse peritoneal macrophages cultured 
with artificial lipoproteins consisting of a cholesterol 
ester and albumin. Since LDL has a variable fatty acid 
and antioxidant composition, this circumvents any such 
variations [25]. These artificial ipoproteins may have a 
naturally-occurring counterpart, since cholesterol ester- 
rich albumin particles have been found in human alh- 
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erosclerotic plaques [26], but they also serve as a model 
of cholesterol esters in LDL. 
Evidence of a handling defect of iron and copper in 
diabetes, as well as an increased oxidation of AA [9], 
implies that AA oxidation may contribute to oxidative 
stress in this disease [l ,2,11]. The effects of AA on the 
events following culture of macrophages with cholest- 
eryl linoleate-containing artificial lipoproteins were 
therefore investigated. 
2. MATERIALS AND METHODS 
Radiochemicals were obtained from Amersham (Aylcsbury, UK). 
All biochemicals were oblained from Sigma (Poole, UK) or Aldrich 
(Gillingham, UK) unless stated otherwise and were of the highest 
purity available. 
The gcneratian of hydroxyl radicals by AA was assessed by moni- 
toring the hydroxylation of benzoic acid to fluorescent products (308 
nm excitalionl410 nm emission) with salicylic acid as a standard [27- 
291, I rnM benzoic acid, 100 mM potassium phosphate (pH 7.1) and 
increasing concentrations ofAA (from 0 to 3 mM) were incubated for 
24 h at 37°C in the presence of 1 PM copper sulphatc under air within 
sealed sterile vessels, 
Fragmentation of bovine serum albumin (BSA; 20 mg/ml) during 
exposure IO AA was used as 3 measure of fret radical damage as 
previously described [28,30]. Albumin (fraction V; Boehringer- 
Mannheim, Mannheim, Germany) was labelled by reductive methyla- 
tion of 0.1% of toral lysinc groups (SO.000 dpm/rng protein) with 
[‘JC]Tormaldehyde and NaCNBH,. FragmentaGon of radiolabelled 
BSA during exposure to AA was monitored by the determination of 
5% trichloroacctic acid (TCA)-soluble radiolabellcd fragments. All 
incubations contained ascorbic acid, 100 mM potassium phosphate 
(pH 7.2) and 10 PM copper sulphaw and were performed at 37°C. 
Peritoneal macrophages were isolated from male BALD/c mice aged 
6-8 weeks as previously described [22]. Cells were resuspended in
RPM1 1640 medium comaining 10% lipoprotein-dcficicnt fetal calf 
serum (LPDFCS) and plated at 2 x IO” cells/cuhure dish. All media 
contained 100 lU/ml penicillin and 1OOygIml streptomycin sulphate. 
Cell cultures were performed in 3 ml (5 cm diameter) culture dishes 
(Anumbra dishes, Payne, Slough, Berks, UK) throughout. The macro- 
phages were allowed to adhere by incubating for 3 h. Non-adherent 
cells were removed by washing with fresh medium. Fresh medium was 
then added, and cells incubated overnight at 37°C in an atmosphere 
of 5% CO1 prior to introduction of lipoprotein. The cultures were then 
incubated with lipoprotein for 24 h. 
Cholesteryl-IinoleateIbovine serum albumin (CLIBSA) was pre- 
pared as previously described [22]. The molar ratio of CL to BSA was 
60: 1. BSA was used at IO mgIm1 in phosphate=buffered saline (PBS). 
CL was dissolved in acetone (BDHmAnalar), added to IO m&ml BSA 
whilst vortexing and then sonicated for 1 min. Acetone was evapo- 
rated by gassing wilh nitrogen. 
Cells were harvesled by removing the medium and adding 3 ml 
0.33% ethylcncdiamine tctraacetic acid (EDTA) in RPM1 with 10% 
LPDFCS. After I5 min. his medium was removed and retained. Re- 
maining adherent cells were scrape-harvested in 3 ml of Hanks’ bal- 
anced salt solution. A cell pellet was prepared. from lhe EDTAm 
containing medium and scrape-harvested cells, by ccntril’ugation. 
Cells wcrc rcsuspcndcd in 0.25 ml fixative (I .5% formaldehyde, 0.1% 
BSA in PBS) by vortexing. The fixed cells were stored at 4OC and 
analysed within 2 weeks, during which period no change in Iluorcs- 
cence is observed. Fluorescence in cell5 was analysed using 3 FACSur 
Plus flow cytometer (Becton Dickinsor! m.~caocyto.metry Systems, 
San Jose, CA, USA) equipped with a Spectra Physics X25 argon ion 
laser. The laser was tuned to emit 300 mW ol’ light in the UV wave- 
lengths 351.1-363.8 nm. Inlact macropbagcs were identified by for- 
wzrd light scalter. Computerised srieciiou of live populations ofmuc- 
[Ascorbic acid] (uM) 
Fig. 1. Effect of ascorbic acid on bcnzoic acid hydroxylation. Values 
in all figures are the mean f SD from 3 cxpcriments, and in Figs. l-3, 
plotted against a non-linear s-axis of AA concentration. 
rophagcs was determined using propidium iodide LO stain dead cells. 
Fluorescence was monitored using a 490 nm long-pass filter in front 
of the detector. Results were expressed relative to a control in which 
cells were exposed 10 medium alone, since this instrument, in common 
with all Iluorimelcrs, measures light intensities in arbitrary units. 
3. RESULTS AND DISCUSSION 
The hydroxylation of benzoic acid to fluorescent de- 
rivatives is used to monitor the presence of hydroxyl 
radicals [27,28]. Incubation of benzoic acid with AA in 
the presence of Cu(I1) showed maximum hydroxylation 
at an AA concentration of 100 PM (Fig. I). This sug- 
gests that AA Ilas either pro- GP antioxidani CharXietis- 
tics depending on concentration. The same was true for 
BSA fragmentation, a measure of protein oxidation 
under these circumstances [28,30], which was maximal 
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Fig. 2, EiTcct of ascorbic acid on protein fragmentation. 
at 50-100 ,uM AA (Fig. 2). EDTA inhibited the frag- 
mentation by 90% but did not affect the concentration 
producing maximal fragmentation. 
The accumulation of ceroid in macrophages exposed 
to oxidisable lipoprotein is a model system for investi- 
gating oxidative events relevant o atherosclerosis [25]. 
Using this model we have shown that vitamin E inhibits 
ceroid accumulation (Hunt et al., submitted for publica- 
tion). Murk peritoneal macrophages exposed to CL/ 
DSA led to ceroid accumulation, assessed by flow cy- 
tometry (Fig. 3). Fig. 3 also shows the effect of including 
various concentrations of AA with or without EDTA. 
Again, AA can either elevate or inhibit ceroid accumu- 
lation depending on AA concentration. However, inhi- 
bition was evident only at the non-physiologically high 
concentrations of 3 mM. In the presence of EDTA, AA 
inhibited at lower concentrations (Fig. 3). Thus, AA 
behaves as an antioxidant only in the near absence of 
catalytically active transition metals. When transition 
metals are available, the oxidation of unsaturated fatty 
acids is favoured and physioIogica1 concentrations of 
AA are pro-oxidant. This suggests that the pro-oxidant 
activity of AA requires transition metals. This is sup- 
ported by the experiment shown in Fig. 4. Cu(I1) in- 
creased ceroid accumulation modestly in the absence of 
AA but the presence of 3 mM AA led to greatly in- 
creased ceroid accumulation. 
These results lead us to suggest hat, in the presence 
of transition metals, AA behaves as a pro-oxidant and 
therefore might even contribute to the increased severity 
of atherosclerosis n diabetes mellitus. Short-term sup 
plementation of AA in diabetic individuals with and 
without complications improved their plasma AA levels 
only transiently [9]. Indeed, such studies also showed 
that AA supplements led to an increase in products of 
AA oxidation [9]. This suggests that AA supplementa- 
tion does little to alleviate oxidative stress in the short 
term and might even contribute to it. Also, oral AA can 
- CL-EISA 
- CL-BSA + lOOuh14 EDTA 
[Ascorbic wid] (uM) 
Fig. 3. Efkct of AA on ceroid accumuivGur. in mncrophogcs. 
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Fig. 4, Effect of cupric ions on ceroid accumulation i  macrophagcs, 
in the presence and absence of AA. 
cause increased iron absorption and be harmFu1 instates 
of iron overload [3 11. Since altered handling of iron has 
been shown in diabetes, along with beneficial effects of 
metal chelators [32], there remains a distinct possibility 
that ascorbic acid supplementation may do more harm 
than good. 
Albeit using only an in vitro model of certain oxida- 
tive events, these studies suggest hat ascorbic acid en- 
hances oxidative reactions which may be pertinent o 
the deve1opmrr.t of atherosclerosis. Therefore, prior to 
advocating ascorbic acid supplementation to alleviate 
oxidative stress in diabetic individuals, there is a real 
need to establish whether the antioxidant activity of 
ascorbate indeed predominates in viva. Long-term 
ascorbic acid supplementation could theoretically exac- 
erbate oxidative stress, and actuaiiy enhance t.he risk of 
the life-threatening diabetic omplication, atherosclero- 
sis. 
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